Form 4: Cue Biopharma Executive Granted Stock Options

Daniel G. Baker, Chief Development Officer at Cue Biopharma, Inc., has been granted 100,000 stock options with an exercise price of $0.29.

Summary

• Daniel G. Baker, Chief Development Officer at Cue Biopharma, Inc. (CUE), was granted 100,000 stock options on April 9, 2026.
• The stock options have an exercise price of $0.29 per share.
• These options are exercisable over four years, with 25% vesting on the first anniversary of the grant date and the remaining vesting in equal, semi-annual installments thereafter.
• The underlying securities are 100,000 shares of Common Stock.
• The expiration date for these options is April 8, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on routine executive compensation in the form of stock options, without providing new financial performance data or strategic shifts.

Positives

• Grant of stock options to a key executive, indicating potential alignment of executive interests with shareholder value.
• The exercise price of $0.29 suggests the options are granted at a price that may offer upside potential for the executive if the stock price increases significantly.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The value of the stock options is contingent on the future performance of Cue Biopharma's stock price, which is subject to market volatility and company-specific risks.
• The vesting schedule means the executive will not have full control over all options immediately, mitigating immediate sell-off risk but also indicating a phased commitment.

Future Outlook

The future outlook for the stock options is dependent on the company's performance and stock price appreciation. The vesting schedule indicates a long-term incentive for the executive.

Industry Context

StockSavvy.ai notes that the granting of stock options to executives is a common practice in the biopharmaceutical industry to incentivize performance and retain talent, especially in companies focused on research and development where long-term value creation is key.

Stakeholder Impact

• Shareholders: The grant of options aligns executive incentives with potential future stock price appreciation, which can benefit shareholders if the company performs well. However, it also represents potential future dilution if options are exercised.
• Employees: This filing does not directly impact other employees, but it reflects the company's compensation strategy for its senior leadership.
• Management: The executive receives a performance-based incentive tied to the company's stock performance.

Next Steps

• The executive will work towards meeting the vesting conditions for the stock options.
• The company will continue its development activities, which will influence the stock price and the value of these options.

Key Dates

Keywords

Cue Biopharma, CUE, Form 4, Stock Options, Executive Compensation, Insider Trading, Securities, Vesting Schedule, Daniel G. Baker